This video presentation from the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute provides a concise 23-minute summary of essential bladder cancer clinical updates from GU ASCO 2025. Explore key findings including the CheckMate274 trial showing maintained disease-free survival benefits with adjuvant Nivolumab for high-risk resected bladder cancer, the NIAGARA study demonstrating higher complete response rates with perioperative Durvalumab plus chemotherapy for muscle invasive bladder cancer, and promising results from the INDUCT trial on neoadjuvant Durvalumab with chemotherapy in upper tract urothelial carcinoma.